tiprankstipranks
Advertisement
Advertisement

TARS Stock Latest News

Tarsus Advances TP-05 Lyme Prevention Trial, Setting Up a New Mid-Stage Catalyst for TARS Investors
Company AnnouncementsTarsus Advances TP-05 Lyme Prevention Trial, Setting Up a New Mid-Stage Catalyst for TARS Investors
9d ago
TARS
Tarsus Pharmaceuticals Earnings Call Signals Durable Growth
PremiumCompany Announcements
Tarsus Pharmaceuticals Earnings Call Signals Durable Growth
23d ago
TARS
Tarsus Pharmaceuticals reports Q1 EPS (16c), consensus (40c)
PremiumThe Fly
Tarsus Pharmaceuticals reports Q1 EPS (16c), consensus (40c)
23d ago
TARS
3 Best Growth Stocks to Buy in May 2026, According to Analysts
PremiumMarket News
3 Best Growth Stocks to Buy in May 2026, According to Analysts
25d ago
NFLX
PANW
Buy Rating Reaffirmed on XDEMVY as Inventory Dynamics Seen as Transient and $88 Price Target Remains Unchanged
PremiumRatings
Buy Rating Reaffirmed on XDEMVY as Inventory Dynamics Seen as Transient and $88 Price Target Remains Unchanged
25d ago
TARS
Tarsus Pharmaceuticals assumed with an Outperform at Oppenheimer
PremiumThe FlyTarsus Pharmaceuticals assumed with an Outperform at Oppenheimer
1M ago
TARS
Buy Rating Backed by Blockbuster Xdemvy Launch and TP-05 Lyme Prevention Opportunity
Premium
Ratings
Buy Rating Backed by Blockbuster Xdemvy Launch and TP-05 Lyme Prevention Opportunity
2M ago
TARS
Tarsus Pharmaceuticals doses first participant in TP-05 trial
Premium
The Fly
Tarsus Pharmaceuticals doses first participant in TP-05 trial
2M ago
TARS
Tarsus Pharmaceuticals price target raised to $101 from $100 at Mizuho
PremiumThe Fly
Tarsus Pharmaceuticals price target raised to $101 from $100 at Mizuho
2M ago
TARS
Tarsus Pharmaceuticals to receive $15M milestone on China TP-03 approval
PremiumThe Fly
Tarsus Pharmaceuticals to receive $15M milestone on China TP-03 approval
2M ago
TARS
Tarsus Pharmaceuticals Bets Big on XDEMVY Growth
PremiumCompany Announcements
Tarsus Pharmaceuticals Bets Big on XDEMVY Growth
3M ago
TARS
Tarsus Pharmaceuticals price target raised to $105 from $95 at Oppenheimer
PremiumThe Fly
Tarsus Pharmaceuticals price target raised to $105 from $95 at Oppenheimer
3M ago
TARS
Tarsus Pharmaceuticals price target raised to $90 from $87 at Guggenheim
PremiumThe FlyTarsus Pharmaceuticals price target raised to $90 from $87 at Guggenheim
3M ago
TARS
Tarsus Pharmaceuticals rises 11.6%
Premium
The Fly
Tarsus Pharmaceuticals rises 11.6%
3M ago
TARS
Tarsus Pharmaceuticals price target raised to $90 from $88 at BofA
Premium
The Fly
Tarsus Pharmaceuticals price target raised to $90 from $88 at BofA
3M ago
TARS
Sustained Growth Outlook for Tarsus Driven by XDEMVY’s Rapid Ramp and Expanding Lotilaner Pipeline
PremiumRatings
Sustained Growth Outlook for Tarsus Driven by XDEMVY’s Rapid Ramp and Expanding Lotilaner Pipeline
3M ago
TARS
Tarsus: Strong Xdemvy Launch, Upgraded Long‑Term Outlook, and Underappreciated Earnings Power Support Buy Rating
PremiumRatings
Tarsus: Strong Xdemvy Launch, Upgraded Long‑Term Outlook, and Underappreciated Earnings Power Support Buy Rating
3M ago
TARS
Tarsus: Raising Peak Xdemvy Outlook to $2B+ on Strong Q4 Momentum and Pipeline Upside
PremiumRatings
Tarsus: Raising Peak Xdemvy Outlook to $2B+ on Strong Q4 Momentum and Pipeline Upside
3M ago
TARS
Tarsus Pharmaceuticals reports Q4 EPS (20c), consensus (13c)
PremiumThe Fly
Tarsus Pharmaceuticals reports Q4 EPS (20c), consensus (13c)
3M ago
TARS
TARS Upcoming Earnings Report: What to Expect?
PremiumPre-EarningsTARS Upcoming Earnings Report: What to Expect?
3M ago
TARS
Tarsus Pharmaceuticals Adds Industry Veteran to Board
Premium
Company Announcements
Tarsus Pharmaceuticals Adds Industry Veteran to Board
3M ago
8K
TARS
Tarsus Pharmaceuticals appoints Pyott to Board of Directors
Premium
The Fly
Tarsus Pharmaceuticals appoints Pyott to Board of Directors
3M ago
TARS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >